7 withdrawn. 7 Phase 2, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Withdrawn 7 |
| Phase 3 | 2 | Withdrawn 2 |
Follow Conjunctivitis: new trials by email Literature Review of Conjunctivitis trials Research Report on Conjunctivitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of Grass-SPIRE Registration Study Grass-SPIRE, Placebo - Rhinitis, Conjunctivitis | Phase 2 / Phase 3 | Withdrawn | Circassia Limited | 2016-05-01 | 2016-06-23 | |
| Nepal Elimination of Trachoma Study Azithromycin - Trachoma | Phase 2 / Phase 3 | Withdrawn | University of California, San Francisco | 2014-08-01 | 2015-05-21 | |
| Efficacy and Safety of PRO-118 Ophthalmic Solution in Allergic Conjunctivitis PRO-118 Ophthalmic Solution 0.015%, PRO-118 Ophthalmic Solution 0.015 %, PRO-118 Ophthalmic Solution 0.020 % - Ocular Itching, Ocular Allergy | Phase 2 | Withdrawn | Laboratorios Sophia S.A de C.V. | 2011-03-01 | 2018-10-02 | |
| Safety and Efficacy of AL-15469A 0.5% / AL-6515 0.3% Ophthalmic Suspension for Treatment of Bacterial Conjunctivitis AL-15469A 0.5% and AL-6515 0.3% Ophthalmic Suspension, AL-15469A 0.5%, AL-6515 0.3% - Bacterial Conjunctivitis | Phase 2 | Withdrawn | Alcon Research | 2011-01-01 | 2011-12-01 | |
| A Study Of Tasocitinib In Dry Eye Subjects Tasocitinib, vehicle for Tasocitinib - Keratoconjunctivitis Sicca | Phase 2 | Withdrawn | Pfizer | 2010-12-01 | 2018-11-29 | |
| To Evaluate the Efficacy of AL-38583 in the Reduction of Tear Eosinophil Count Following Conjunctival Allergen Challenge AL38583 Ophthalmic Solution, Maxidex, Vehicle - Allergic Conjunctivitis | Phase 2 | Withdrawn | Alcon Research | 2009-05-01 | 2012-03-06 | |
| A Study Of The Safety And Effectiveness Of A New Treatment For Allergic Conjunctivitis Ketotifen/vasoconstrictor - Allergic Conjunctivitis | Phase 2 | Withdrawn | Bausch & Lomb Incorporated | 2015-02-20 |
Conjunctivitis, Allergic (3) · Conjunctivitis, Bacterial (1) · Dry Eye Syndromes (1) · Hypersensitivity (1) · Keratoconjunctivitis Sicca (1) · Rhinitis (1) · Trachoma (1)
Conjunctival Diseases (7) · Eye Diseases (7) · Immune System Diseases (4) · Hypersensitivity (3) · Hypersensitivity, Immediate (3) · Infections (3) · Bacterial Infections (2) · Bacterial Infections and Mycoses (2) · Corneal Diseases (2) · Eye Infections (2) · Eye Infections, Bacterial (2) · Chlamydia Infections (1) · Chlamydiaceae Infections (1) · Conjunctivitis, Bacterial (1)
Azithromycin (1) · Dexamethasone (1) · Ketotifen (1) · Vasoconstrictor Agents (1) · tofacitinib (1)
Alcon Research (2) · Bausch & Lomb Incorporated (1) · Circassia Limited (1) · Laboratorios Sophia S.A de C.V. (1) · Pfizer (1) · University of California, San Francisco (1)
Mexico (1) · Nepal (1) · United States (1)
Bruce D Gaynor, MD (1) · David Bernstein, MD (1) · Miriam Becerra-Cotta, MD (1)
K23EY019881 (1)